This suggests that OSM expression modulates the efficacy of immunotherapy in CCA patients by influencing the immune regulatory checkpoints CTLA4, HAVCR2, PDL1, however, the mechanism is under further study. Here, HAVCR2 is linked to cholangiocarcinoma.